Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 2/5 criteria met. Data as of 17/09/2026.
- ✅ Price trend passed
- ⚠️ Mixed growth
- ❌ Debt failed
- ✅ P/E passed
- ❌ Correction failed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2018 → 2019: 23.84%
Price change 2019 → 2020: -4.63%
Price change 2020 → 2021: -2.15%
Price change 2021 → 2022: 16.74%
Price change 2022 → 2023: 9.66%
Price change 2023 → 2024: -9.51%
Price change 2024 → 2025: 25.58%
Price change 2025 → 2026: 33.85%
Price change 2026 (year to date): 33.72%
Financial growth
Revenue CAGR (8 years): 6.43%
Earnings CAGR (8 years): -1.21%
Growth status: positive trend (>1%/yr) in revenue OR earnings, but not both.
Debt
Debt-to-equity ratio: 6.31
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 18.02
P/E < 25.0 (maximum threshold).
Correction (6 months)
Current correction: 1.29% from the high over 6 months.
Insufficient correction (< 10.0%).
Criteria of the Investlytic model
- / 5Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Amgen Inc. | 19.6 | 6.31 | +6.1 % | 🔒 |
| AstraZeneca PLC | 18.5 | 0.61 | +3.9 % | – |
| Pfizer Inc. | 9.8 | 0.78 | −0.5 % | – |
| AbbVie Inc. | 28.0 | – | +9.5 % | – |
| GSK plc | 11.0 | 1.08 | +0.9 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|